Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein associated with atherosclerotic cardiovascular disease. Niacin and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) both lower Lp(a). The objective of the study was to determine if addition of PCSK9i to background niacin ...
A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, levels of lipoprotein (a). Efforts to prevent atherosclerotic heart ...
3. Ellis KL, Boffa MB, Sahebkar A, et al. The renaissance of lipoprotein(a): brave new world for preventive cardiology? Prog Lipid Res 2017; 68:57–82. 4. Boffa MB, Koschinsky ML. Proprotein convertase subtilisin/kexin type 9 ...
Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) LevelsLipoprotein (a) [Lp(a)] is a prevalent genetic risk factor for coronary artery disease [1] and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated significant Lp(a)-lowering effects [2, 3]....
F. et al. PCSK9 modulates the secretion but not the cellular uptake of lipoprotein (a) ex vivo: an effect blunted by alirocumab. JACC Basic Transl Sci. 1, 419–427 (2016). PubMed PubMed Central Google Scholar Kotani, K. & Banach, M. Lipoprotein(a) and inhibitors of proprotein ...
Abstract ： PCSK9 inhibitors are a new type of drug used to reduce the level of low -density lipoprotein cholesterol. In recent years ， PCSK9 inhibitors have exhibited certain potential in the treatment of ischemic stroke ； however ， the research in ischemic stroke is still in its early ...
10. Koskinas, K. C. et al. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and ...
11.Rivera F,et al. 1068-13-IMPACT OF PCSK-9 INHIBITORS ON LIPOPROTEIN(A): A META-ANALYSIS AND META-REGRESSION OF 47 RANDOMIZED CONTROLLED TRIALS. Presented at ACC.24. 12.Shatla I,et al.1492-217 / 217 - EARLY ADMINISTRATION OF PCSK-9 INHIBITOR FOR ACUTE CORONARY SYNDROME: A SYSTEMATIC...
低密度脂蛋白(low-density lipoprotein, LDL)是一种脂蛋白颗粒,是运输胆固醇的载体。目前已有研究发现,升高的LDL胆固醇水平显著升高心梗和动脉粥样硬化性心血管疾病的风险[1]。因此,LDL胆固醇(LDL cholesterol, LDL-C)通常也被认为是一种“...
with the aim of reducing their risk of future cardiovascular incidents by administering PCSK9 inhibitors. PCSK9 inhibitors are a type of medication that lowers the levels of low-density lipoprotein cholesterol (LDL-C, also known as "bad" cholesterol) in the blood, which helps decrease the risk...